Loading…
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $149M | $-28M | $-39M | $-21M | -148.6% | 99.2% | - |
| 2024 | $75M | $-35M | $-44M | $-32M | -137.5% | 5.0% | - |
| 2023 | $71M | $-23M | $-30M | $-34M | -88.3% | 9.4% | - |
| 2022 | $65M | $-32M | $-37M | $-34M | -65.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 65.21 | 71.35 | 74.89 | 149.16 |
| Cost Of Revenue | 15.48 | 19.64 | 20.73 | 76.85 |
| Gross Profit | 49.72 | 51.70 | 54.16 | 72.31 |
| Operating Expense | 84.83 | 82.26 | 88.72 | 103.74 |
| Operating Income | -35.11 | -30.55 | -34.56 | -31.44 |
| EBITDA | -31.96 | -23.36 | -35.17 | -28.05 |
| EBIT | -33.61 | -25.36 | -37.24 | -31.52 |
| Pretax Income | -37.21 | -30.16 | -43.74 | -39.12 |
| Net Income | -37.16 | -30.19 | -43.71 | -39 |
| Net Income Common Stockholders | -37.16 | -30.19 | -43.71 | -39 |
| Total Expenses | 100.32 | 101.90 | 109.45 | 180.59 |
| Interest Expense | 3.60 | 4.80 | 6.50 | 7.60 |
| Research And Development | 9.34 | 9.52 | 12.77 | 6.58 |
| Selling General And Administration | 75.50 | 72.74 | 75.95 | 97.16 |
| Normalized EBITDA | -31.96 | -23.36 | -30.74 | -28.05 |
| Normalized Income | -37.16 | -30.19 | -39.28 | -39 |
| Basic EPS | -1.38 | -1.05 | -1.37 | 0 |
| Diluted EPS | -1.38 | -1.05 | -1.37 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -4.43 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -4.43 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -37.16 | -30.19 | -43.71 | -39 |
| Reconciled Depreciation | 1.65 | 2.01 | 2.07 | 3.46 |
| Reconciled Cost Of Revenue | 15.48 | 19.64 | 20.73 | 76.85 |
| Net Interest Income | -4.30 | -5.40 | -7.30 | -8.40 |
| Net Income From Continuing And Discontinued Operation | -37.16 | -30.19 | -43.71 | -39 |
| Total Operating Income As Reported | -35.11 | -30.55 | -34.56 | -31.44 |
| Diluted Average Shares | 26.90 | 28.66 | 31.63 | 0 |
| Basic Average Shares | 26.90 | 28.66 | 31.63 | 0 |
| Diluted NI Availto Com Stockholders | -37.16 | -30.19 | -43.71 | -39 |
| Minority Interests | 0 | 0 | 0.02 | 0.14 |
| Net Income Including Noncontrolling Interests | -37.21 | -30.16 | -43.74 | -39.12 |
| Net Income Continuous Operations | -37.21 | -30.16 | -43.74 | -39.12 |
| Other Income Expense | 2.20 | 5.79 | -1.88 | 0.72 |
| Other Non Operating Income Expenses | 2.20 | 5.79 | 2.55 | 0.72 |
| Special Income Charges | 0 | 0 | -4.43 | 0 |
| Other Special Charges | 0 | 0 | 4.43 | 0 |
| Net Non Operating Interest Income Expense | -4.30 | -5.40 | -7.30 | -8.40 |
| Total Other Finance Cost | 0.70 | 0.60 | 0.80 | 0.80 |
| Interest Expense Non Operating | 3.60 | 4.80 | 6.50 | 7.60 |
| Selling And Marketing Expense | 49.98 | 47.32 | 45.63 | 47.46 |
| General And Administrative Expense | 25.52 | 25.43 | 30.32 | 49.70 |
| Other Gand A | 25.52 | 25.43 | 30.32 | 49.70 |
| Operating Revenue | 65.21 | 71.35 | 74.89 | 149.16 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Neuronetics, Inc.this co. | STIM | $118M | - | 5.25 | -148.6% | -6.65 |
| TuHURA Biosciences, Inc. | HURA | $134M | - | 6.03 | -143.6% | -4.67 |
| AVITA Medical, Inc. | RCEL | $130M | - | -7.76 | 291.8% | -3.91 |
| The Joint Corp. | JYNT | $127M | - | 8.33 | 19.3% | 140.09 |
| Nano-X Imaging Ltd. | NNOX | $119M | - | 0.85 |
| -28.3% |
| -1.41 |
| OptimizeRx Corporation | OPRX | $115M | 22.74 | 0.90 | 4.0% | 7.20 |
| Aardvark Therapeutics, Inc. | AARD | $114M | - | 1.07 | -54.0% | -0.07 |
| Cardiff Oncology, Inc. | CRDF | $111M | - | 2.44 | -101.0% | -1.10 |
| Definitive Healthcare Corp. | DH | $99M | - | 0.35 | -36.7% | 5.27 |
| Peer Median | - | 22.74 | 0.98 | -32.5% | -0.58 | |